Status:
UNKNOWN
Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI
Lead Sponsor:
Assiut University
Conditions:
CML, Chronic Phase
Eligibility:
All Genders
18-75 years
Brief Summary
Metabolic alternation and clinicohematological characteristic in chronic phase CML in patient treated with TKI
Detailed Description
Chronic myeloid leukemia (CML), a clonal hematopoietic stem cell malignancy, is characterized by unique translocation leading to the formation of the Philadelphia chromo- some.Because of the specific ...
Eligibility Criteria
Inclusion
- Patient newly diagnosed with CML and received TKI
Exclusion
- patient previously diagnosed CML and started treatment or in post treatment follow up
Key Trial Info
Start Date :
November 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 30 2025
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT06121765
Start Date
November 1 2023
End Date
November 30 2025
Last Update
November 8 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.